Anu Wallecha
1. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.Souders NC, Sewell DA, Pan ZK, ...Hussain SF, Rodriguez A, Wallecha A, Paterson Y
Cancer Immun. 2007 Feb 6. 7: 2
2. Development of a Listeria monocytogenes based vaccine against prostate cancer.
Shahabi V, Reyes-Reyes M, Wallecha A, ...Rivera S, Paterson Y, Maciag P
Cancer Immunol Immunother. 2008 Sep. 57(9): 1301-13
3. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.
Wallecha A, Maciag PC, Rivera S, ...Paterson Y, Shahabi V
Clin Vaccine Immunol. 2009 Jan. 16(1): 96-103
4. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
Seavey MM, Pan ZK, Maciag PC, ...Wallecha A, Rivera S, Paterson Y, Shahabi V
Clin Cancer Res. 2009 Feb 1. 15(3): 924-32
5. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
Wallecha A, Carroll KD, Maciag PC, ...Rivera S, Shahabi V, Paterson Y
Adv Appl Microbiol. 2009. 66: 1-27
Pages:
1
